Compare RKLB & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RKLB | ILMN |
|---|---|---|
| Founded | 2006 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 37.0B |
| IPO Year | 2020 | 2000 |
| Metric | RKLB | ILMN |
|---|---|---|
| Price | $52.81 | $269.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 21 |
| Target Price | $102.26 | ★ $241.05 |
| AVG Volume (30 Days) | ★ 16.4M | 2.5M |
| Earning Date | 11-09-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.63 | ★ 170.87 |
| EPS | N/A | ★ 2.22 |
| Revenue | $601,799,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $59.29 | $6.48 |
| Revenue Next Year | $38.82 | $6.46 |
| P/E Ratio | ★ N/A | $120.92 |
| Revenue Growth | ★ 37.96 | N/A |
| 52 Week Low | $37.57 | $94.00 |
| 52 Week High | $150.85 | $309.35 |
| Indicator | RKLB | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 33.60 | 54.67 |
| Support Level | N/A | $254.00 |
| Resistance Level | $77.02 | $309.35 |
| Average True Range (ATR) | 3.29 | 15.36 |
| MACD | -1.43 | -2.32 |
| Stochastic Oscillator | 11.99 | 27.62 |
Rocket Lab Corp is engaged in space, building rockets, and spacecraft. It provides end-to-end mission services that provide frequent and reliable access to space for civil, defense, and commercial markets. It designs and manufactures the Electron and Neutron launch vehicles and Photon satellite platform. Rocket Lab's Electron launch vehicle has delivered multiple satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. The business operates in two segments Launch Services and Space Systems. Geographically it serves Japan, and rest of the world and earns key revenue from the United States.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.